ChemoCentryx to Present at the BioCentury NewsMakers in the Biotech Industry Conference
MOUNTAIN VIEW, Calif., Aug. 30, 2012 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the BioCentury NewsMakers in the Biotech Industry Conference on Friday, September 7, 2012, at 9:30 a.m. Eastern Time at the Millennium Broadway Hotel & Conference Center in New York, NY.
A live audio webcast of the presentation can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. Following the live presentation, a replay of the webcast will be available on the Company's website for two weeks following the conference.
ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. The Company's most advanced drug candidate, vercirnon (also known as Traficet-EN, CCX282 or GSK1605786), a specific CCR9 inhibitor, completed a multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease, where it demonstrated the ability to induce a clinical response and to maintain clinical remission, and is now in Phase III clinical development. The Company's lead independent drug candidate, CCX140, a CCR2 inhibitor, has been shown to be safe and well tolerated while demonstrating clinical activity on glycemic indices in a Phase II clinical trial in type 2 diabetics, and is now in Phase II clinical development for the treatment of diabetic nephropathy. Other clinical programs include CCX354 (also known as GSK2941266), a CCR1 inhibitor which successfully completed a Phase II clinical trial for the treatment of rheumatoid arthritis, and CCX168, a C5aR inhibitor in Phase II clinical development for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. ChemoCentryx also has several programs in advanced preclinical development.
CCXI - G
Source: ChemoCentryx, Inc.
Susan M. Kanaya
Senior Vice President, Finance and
Chief Financial Officer; or
Markus J. Cappel, Ph.D.
Chief Business Officer